Latest Ratios: P/E Ratio -0.7x · EV/EBITDA N/A · ROE -100.4%. (2000–2026 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $41M | $48M | $86M | $98M | $330M | $525M | $708M | $577M | $467M | $853M | $410M |
| Enterprise Value | $20M | $27M | $33M | $44M | $227M | $414M | $589M | $473M | $366M | $775M | $352M |
| P/E Ratio → | -0.70 | — | — | — | 64.96 | 24.81 | 23.14 | 22.31 | 12.38 | 22.94 | 17.21 |
| P/S Ratio | 0.23 | 0.27 | 0.38 | 0.36 | 1.29 | 1.92 | 2.33 | 2.03 | 1.65 | 3.12 | 1.65 |
| P/B Ratio | 1.39 | 1.65 | 1.01 | 1.01 | 3.00 | 3.69 | 5.01 | 4.44 | 3.47 | 7.37 | 4.40 |
| P/FCF | — | — | — | — | 14.65 | 31.36 | 18.80 | 15.80 | 10.49 | 23.26 | 11.21 |
| P/OCF | — | — | 18.29 | 22.63 | 11.88 | 28.39 | 17.66 | 14.86 | 10.34 | 22.82 | 8.69 |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 0.15 | 0.14 | 0.16 | 0.89 | 1.51 | 1.94 | 1.67 | 1.29 | 2.83 | 1.41 |
| EV / EBITDA | — | — | 5.91 | 466.54 | 22.50 | 14.56 | 17.87 | 14.25 | 7.57 | 14.29 | 9.05 |
| EV / EBIT | — | — | — | — | 30.52 | 15.30 | 19.29 | 13.97 | 7.46 | 14.41 | 9.27 |
| EV / FCF | — | — | — | — | 10.08 | 24.73 | 15.65 | 12.96 | 8.23 | 21.13 | 9.61 |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 28.1% | 28.1% | 30.5% | 28.4% | 27.7% | 27.6% | 27.8% | 28.6% | 33.6% | 35.7% | 31.8% |
| Operating Margin | -17.5% | -17.5% | -0.7% | -2.5% | 2.6% | 9.4% | 10.1% | 10.9% | 16.3% | 19.0% | 15.0% |
| Net Profit Margin | -32.0% | -32.0% | -2.8% | -2.7% | 2.0% | 7.7% | 7.9% | 9.1% | 13.3% | 13.6% | 9.6% |
| Metric | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -100.4% | -100.4% | -6.9% | -7.2% | 4.1% | 14.9% | 17.6% | 19.5% | 30.1% | 35.7% | 27.0% |
| ROA | -49.8% | -49.8% | -3.9% | -4.4% | 3.0% | 11.6% | 14.0% | 16.7% | 26.1% | 30.1% | 23.5% |
| ROIC | -119.4% | -119.4% | -3.1% | -21.0% | 25.9% | 71.9% | 93.8% | 76.9% | 96.3% | 108.0% | 70.1% |
| ROCE | -54.6% | -54.6% | -1.7% | -6.6% | 5.1% | 18.0% | 22.3% | 23.2% | 36.6% | 49.4% | 42.2% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.02 | 0.02 | 0.01 | 0.02 | 0.01 | — | — | — | — | — | — |
| Debt / EBITDA | — | — | 0.18 | 15.47 | 0.10 | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.72 | -0.63 | -0.56 | -0.94 | -0.78 | -0.84 | -0.80 | -0.75 | -0.67 | -0.63 |
| Net Debt / EBITDA | — | — | -9.75 | -572.79 | -10.21 | -3.90 | -3.60 | -3.12 | -2.08 | -1.44 | -1.51 |
| Debt / FCF | — | — | — | — | -4.57 | -6.63 | -3.15 | -2.84 | -2.26 | -2.12 | -1.60 |
| Interest Coverage | — | — | — | — | — | — | 25.23 | — | — | — | — |
Net cash position: cash ($21M) exceeds total debt ($535000)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.84 | 0.84 | 1.26 | 1.30 | 2.27 | 4.55 | 3.59 | 5.30 | 6.79 | 5.81 | 4.46 |
| Quick Ratio | 0.58 | 0.58 | 1.00 | 0.90 | 1.94 | 3.57 | 2.82 | 4.57 | 5.64 | 4.52 | 3.35 |
| Cash Ratio | 0.41 | 0.41 | 0.87 | 0.77 | 1.81 | 3.35 | 2.64 | 4.26 | 5.40 | 4.30 | 3.20 |
| Asset Turnover | — | 2.20 | 1.53 | 1.61 | 1.51 | 1.55 | 1.62 | 1.83 | 1.84 | 2.03 | 2.21 |
| Inventory Turnover | 9.47 | 9.47 | 9.74 | 6.88 | 9.77 | 6.10 | 6.37 | 11.34 | 8.80 | 7.54 | 8.40 |
| Days Sales Outstanding | — | 3.89 | 3.73 | 4.37 | 2.48 | 2.55 | 3.11 | 4.94 | 3.27 | 3.06 | 2.65 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | 0.1% | 0.0% | 0.2% | 12.7% | 7.4% | 4.6% | 3.2% | 3.8% | 4.7% | 2.0% | 3.8% |
| Payout Ratio | — | — | — | — | 477.4% | 115.6% | 94.8% | 84.3% | 58.1% | 46.9% | 65.1% |
| Metric | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | 1.5% | 4.0% | 4.3% | 4.5% | 8.1% | 4.4% | 5.8% |
| FCF Yield | — | — | — | — | 6.8% | 3.2% | 5.3% | 6.3% | 9.5% | 4.3% | 8.9% |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 2.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.1% | 0.0% | 0.2% | 12.7% | 7.4% | 4.6% | 3.2% | 5.8% | 4.7% | 2.0% | 3.8% |
| Shares Outstanding | — | $21M | $21M | $20M | $20M | $20M | $20M | $20M | $20M | $20M | $20M |
Liquidity and customer churn
According to current market data, PETS trades at a P/S multiple of 0.21, a valuation level that suggests investors have largely abandoned growth expectations and are instead pricing the firm as a distressed asset rather than a viable competitor in the broader pet pharmacy ecosystem.
The absence of a meaningful P/E ratio and the depressed P/S multiple indicate that the market is heavily discounting the company's future earnings potential. This valuation gap compared to peers like Chewy suggests that the market views the current business model as structurally impaired rather than temporarily mispriced.
Based on reported financial statements, the company's ROIC has plummeted to -58.6% in 2026Q4, a stark reversal from historical periods that highlights a profound inability to generate returns on invested capital as the core pharmacy business faces persistent competitive pressure and margin erosion.
The rapid decay in ROIC suggests that the capital deployed into the business is failing to produce value, likely due to the high costs of customer acquisition relative to declining lifetime value. Investors should monitor whether management can stabilize these returns or if further capital impairment is inevitable.
As reported in recent quarterly filings, the company's asset turnover ratio has declined to 0.51, reflecting a significant reduction in the efficiency with which the firm utilizes its asset base to generate revenue compared to its historical performance in more stable operating environments.
The deterioration in asset turnover, coupled with the volatility in the cash conversion cycle, suggests that the company is struggling to optimize its inventory and payables in the face of a shrinking customer base. This inefficiency likely exacerbates the cash burn, as capital remains tied up in slow-moving inventory.
Based on the company's reported figures, the current ratio has fallen to 0.84 as of 2026Q4, indicating that the firm's ability to meet short-term obligations is increasingly compromised as cash reserves dwindle against a backdrop of persistent, significant net losses and operational cash outflows.
The decline in the quick ratio to 0.58 suggests a high dependence on inventory liquidation to satisfy immediate liabilities, which is a precarious position for a retailer facing declining demand. This liquidity profile warrants close investigation, as it leaves little room for error in the event of further revenue shocks.
The P/E ratio is frequently misapplied to PETS, as the current negative earnings and significant restructuring charges render traditional earnings-based valuation metrics largely irrelevant for assessing the company's underlying potential as a niche pharmacy fulfillment partner or a strategic acquisition target for larger healthcare entities.
Investors should instead focus on the company's enterprise value relative to its pharmacy infrastructure and data assets, which may hold value independent of the current retail losses. Relying on P/E in this context obscures the potential for a pivot to a more sustainable, albeit smaller, business model.
Includes 30+ ratios · 27 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying PETS stock.
PetMed Express, Inc.'s current P/E ratio is -0.7x. The historical average is 22.4x.
PetMed Express, Inc.'s return on equity (ROE) is -100.4%. The historical average is 9.5%.
Based on historical data, PetMed Express, Inc. is trading at a P/E of -0.7x. Compare with industry peers and growth rates for a complete picture.
PetMed Express, Inc.'s current dividend yield is 0.05%.
PetMed Express, Inc. has 28.1% gross margin and -17.5% operating margin.